Turn Therapeutics (TTRX) Stock Overview
Operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TTRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Turn Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.54 |
| 52 Week High | US$26.50 |
| 52 Week Low | US$2.57 |
| Beta | 0 |
| 1 Month Change | -6.29% |
| 3 Month Change | 85.96% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| TTRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.2% | 6.0% | -0.8% |
| 1Y | n/a | 59.4% | 20.5% |
Return vs Industry: Insufficient data to determine how TTRX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TTRX performed against the US Market.
Price Volatility
| TTRX volatility | |
|---|---|
| TTRX Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TTRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TTRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2 | Bradley Burnam | turntherapeutics.com |
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025.
Turn Therapeutics Inc. Fundamentals Summary
| TTRX fundamental statistics | |
|---|---|
| Market cap | US$292.52m |
| Earnings (TTM) | -US$8.45m |
| Revenue (TTM) | n/a |
Is TTRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.61m |
| Gross Profit | -US$1.61m |
| Other Expenses | US$6.83m |
| Earnings | -US$8.45m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 882.7% |
How did TTRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 00:54 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Turn Therapeutics Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Rick Bienkowski | Ladenburg Thalmann & Company |